John Foley

3.0k total citations
89 papers, 1.9k citations indexed

About

John Foley is a scholar working on Oncology, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, John Foley has authored 89 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 39 papers in Pathology and Forensic Medicine and 17 papers in Neurology. Recurrent topics in John Foley's work include Polyomavirus and related diseases (35 papers), Multiple Sclerosis Research Studies (33 papers) and Plant Virus Research Studies (9 papers). John Foley is often cited by papers focused on Polyomavirus and related diseases (35 papers), Multiple Sclerosis Research Studies (33 papers) and Plant Virus Research Studies (9 papers). John Foley collaborates with scholars based in United States, Canada and Switzerland. John Foley's co-authors include Robert R. Maronpot, Theodora R. Devereux, M W Anderson, Lindell K. Weaver, Ramona O. Hopkins, James E. Krook, Harry S. Wieand, Ryan R. Metzger, Loren K. Tschetter and Carl G. Kardinal and has published in prestigious journals such as Nature, JAMA and Neurology.

In The Last Decade

John Foley

84 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Foley United States 24 818 560 394 280 258 89 1.9k
Hua Zhao China 29 610 0.7× 389 0.7× 933 2.4× 509 1.8× 212 0.8× 144 2.5k
John C. Michalak United States 19 1.0k 1.3× 242 0.4× 278 0.7× 145 0.5× 367 1.4× 24 1.9k
Zheng Jiang China 27 705 0.9× 211 0.4× 738 1.9× 370 1.3× 385 1.5× 146 2.3k
Miklós Garami Hungary 22 254 0.3× 246 0.4× 809 2.1× 228 0.8× 248 1.0× 117 2.0k
Satoru Yamamoto Japan 26 497 0.6× 481 0.9× 572 1.5× 84 0.3× 872 3.4× 108 2.6k
Mi Jung Kwon South Korea 22 601 0.7× 178 0.3× 590 1.5× 272 1.0× 463 1.8× 202 2.0k
Osamu Kawano Japan 31 672 0.8× 420 0.8× 616 1.6× 239 0.9× 1.3k 4.9× 171 2.8k
Lizhen Wang China 27 676 0.8× 218 0.4× 608 1.5× 223 0.8× 265 1.0× 148 2.4k
Ernesto Di Cesare Italy 33 377 0.5× 479 0.9× 488 1.2× 197 0.7× 609 2.4× 194 3.0k
Michelle Harrison Australia 23 621 0.8× 138 0.2× 255 0.6× 145 0.5× 233 0.9× 88 1.4k

Countries citing papers authored by John Foley

Since Specialization
Citations

This map shows the geographic impact of John Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Foley more than expected).

Fields of papers citing papers by John Foley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Foley. The network helps show where John Foley may publish in the future.

Co-authorship network of co-authors of John Foley

This figure shows the co-authorship network connecting the top 25 collaborators of John Foley. A scholar is included among the top collaborators of John Foley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Foley. John Foley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mao‐Draayer, Yang, Amit Bar‐Or, John Foley, et al.. (2024). Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances in Therapy. 42(1). 395–412. 2 indexed citations
2.
Foley, John, Gilles Defer, Lana Zhovtis Ryerson, et al.. (2024). Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 11(6). e200321–e200321. 2 indexed citations
3.
Qureshi, Ferhan, et al.. (2023). Analytical validation of a multi‐protein, serum‐based assay for disease activity assessments in multiple sclerosis. PROTEOMICS - CLINICAL APPLICATIONS. 17(3). e2200018–e2200018. 13 indexed citations
4.
Ryerson, Lana Zhovtis, John Foley, Gilles Defer, et al.. (2023). Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 72. 104561–104561. 12 indexed citations
5.
6.
Ryerson, Lana Zhovtis, Xiaochun Li, Judith D. Goldberg, et al.. (2020). Pharmacodynamics of natalizumab extended interval dosing in MS. Neurology Neuroimmunology & Neuroinflammation. 7(2). 22 indexed citations
7.
8.
Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 93(15). e1452–e1462. 116 indexed citations
9.
10.
Foley, John, Karleyton C. Evans, Pei‐Ran Ho, et al.. (2019). The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders. 39. 101863–101863. 25 indexed citations
11.
Foley, John, Kavita Nair, Timothy R. Vollmer, et al.. (2017). Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Preference and Adherence. Volume 11. 1035–1048. 19 indexed citations
12.
13.
Foley, John. (2013). Natalizumab Related PML: An Evolving Risk Stratification Paradigm (S30.002). Neurology. 80(7_supplement). 6 indexed citations
14.
Foley, John, Christopher J. Barnes, & Kavita Nair. (2013). Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care Pharmacy. 19(1 Supp A). S16–S23. 2 indexed citations
15.
Rose, John, John Foley, & Noel G. Carlson. (2009). Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology. 11(3). 211–220. 8 indexed citations
16.
Rose, John, John Foley, & Noel G. Carlson. (2008). Monoclonal antibody treatments for multiple sclerosis. Current Neurology and Neuroscience Reports. 8(5). 419–426. 11 indexed citations
17.
Wilwerding, Mary B., Charles L. Loprinzi, James A. Mailliard, et al.. (1995). A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Supportive Care in Cancer. 3(2). 135–138. 88 indexed citations
18.
Gasecki, Andrew P., Raahim Bashir, & John Foley. (1992). Leptomeningeal Carcinomatosis: A Report of 3 Cases and Review of the Literature. European Neurology. 32(2). 74–78. 11 indexed citations
19.
Ingle, James N., J A Mailliard, Daniel J. Schaid, et al.. (1989). Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer. American Journal of Clinical Oncology. 12(6). 474–480. 14 indexed citations
20.
Wan, R. Y., et al.. (1984). Electrochemical Features of the Ferric Sulfate Leaching of CuFeS2/C Aggregates.. Bioconjugate Chemistry. 23(3). 391–416. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hua Zhao Breakdown of academic impact, for papers by John C. Michalak Breakdown of academic impact, for papers by Zheng Jiang Breakdown of academic impact, for papers by Miklós Garami Breakdown of academic impact, for papers by Satoru Yamamoto Breakdown of academic impact, for papers by Mi Jung Kwon Breakdown of academic impact, for papers by Osamu Kawano Breakdown of academic impact, for papers by Lizhen Wang Breakdown of academic impact, for papers by Ernesto Di Cesare Breakdown of academic impact, for papers by Michelle Harrison
Rankless by CCL
2026